This report studies the European nuclear medicine/radiopharmaceuticals market for the forecast period of 2015 to 2020. This market is expected to reach $1.62 Billion by 2020 from $1.09 Billion in 2015, at a CAGR of 8.2% during the forecast period (2015 to 2020).
The radioisotope and stable isotope markets have been segmented according to the type of isotope, and a pplications.Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (Germany, France, Italy, Spain, U.K., Russia, and Rest of Europe) to provide in-depth information on the European scenario.
The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lions share of the SPECT market is taken up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope.
The global radiopharmaceuticals market was worth USD 4.31 Billion in 2020 and is further projected to reach USD 6.43 Billion by 2027, at a CAGR of 6.0% during 2021-2027 (forecast period).
The radiopharmaceuticals market is projected to reach US$ 13,818.17 million by 2028 from US$ 7,550.74 million in 2021; it is expected to grow at a CAGR of 9.0% from 2021 to 2028.
In-depth research of the Radiopharmaceuticals Market helps to provide the relevant emerging trends and growth opportunities – report given by TBRC. https://bit.ly/3mmqkmo
This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Bracco Imaging Bayer Mallinckrodt Nordion Triad Isotopes Lantheus IBA Group
In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Nuclear Medicine/Radiopharmaceuticals Report by Material, Application, and Geography Global Forecast to 2023 is a professional and comprehensive research report on the worlds major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).
The major players covered in the global radiopharmaceuticals market are Siemens Healthcare Private Limited, Bayer, GE Healthcare.... @ @ https://bit.ly/3xiqYIu
This report studies the global market size of Radiopharmaceuticals in Nuclear Medicine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Radiopharmaceuticals in Nuclear Medicine in these regions.
The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021).
The world radiopharmaceuticals market is expected to generate revenue of $8,207.5 million by 2022, the market is currently in its growth stage driven by increasing number of cancer cases and rising awareness about nuclear medicine.
Diagnostic Radiopharmaceuticals & Contrast Media market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Diagnostic Radiopharmaceuticals & Contrast Media market will be able to gain the upper hand as they use the report as a powerful resource.
Nuclear Medicine / Radiopharmaceuticals Market report segmented the global market by Applications (Cancer/Oncology, Cardiac), By Stable Isotopes (Deuterium, C-13), [SPECT/PET Radioisotopes (Technetium, F-18)] & by Geography – Forecasting - 2017
Radiopharmaceuticals in Nuclear Medical market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Radiopharmaceuticals in Nuclear Medical market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.
Global Radiopharmaceuticals Market, By Type (Diagnostic, Therapeutic), Procedural Volumes (Diagnostic Procedures, Therapeutic Procedures), Application, Sources (Nuclear Reactors, Cyclotrons), End User, Geography (North America, Europe, APAC, South America, MEA)– Industry Trends andForecast To 2024
This report studies the Asia-Pacific nuclear medicine market over the forecast period of 2012-2017. The Asia-Pacific radiopharmaceutical market was valued at $500.8 million in 2012 and is poised to reach $824.9 million by 2017 at a CAGR of 10.5%. Similar to the global nuclear medicine market, the Asia-Pacific region is also minimizing its dependency on nuclear reactor by introducing hospital-based cyclotron facilities. This paves the way for novel isotopes such as Tl-201, F-18, and Rb-82 to capitalize on opportunities in the growing diagnostics market. Besides the gigantic Tc-99m market, florbetapir F 18 and F18-FDG are gaining popularity through their applications for Alzheimer’s disease and diagnosis of brain tumors. Nihon Medi Physics, Covidien, Fujifilm, and ANSTO contributed more than 75 % to the APAC radiopharmaceuticals market in 2012.
Global Radiopharmaceuticals Market, According to Data Bridge Market Research new Market report “By Type (Diagnostic, Therapeutic), Procedural Volumes (Diagnostic Procedures, Therapeutic Procedures), Application, Sources (Nuclear Reactors, Cyclotrons), End User, Geography (North America, Europe, APAC, South America, MEA)–Industry Trends and Forecast To 2024″ is projected to reach USD 9.49 billion by 2024 from USD 4.87 billion in 2016, at a CAGR of 8.7% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
Global Radiopharmaceuticals Market According to Data Bridge Market Research new Market report– Industry Trends and Forecast is projected to reach USD 10.57 billion by 2025, at a CAGR of 9.0% during the forecast period of 2018 to 2025.
Breast cancer remains a formidable health challenge globally, prompting relentless efforts in early detection and treatment. Amidst the array of screening modalities, molecular breast imaging (MBI) emerges as a promising technique, offering enhanced sensitivity in detecting breast abnormalities. As the healthcare landscape evolves, it becomes crucial to delve into the molecular breast imaging market, analyzing its current state, growth trajectories, and future potential.
The Asia-Pacific nuclear medicine market size was valued at $4,116.43 million in 2020, and is projected to reach $8,957.89 million by 2028, registering a CAGR of 10.4% from 2021 to 2028.
Nuclear Medicine / Radiopharmaceuticals Market report segmented the global market by Applications (Cancer/Oncology, Cardiac), By Stable Isotopes (Deuterium, C-13), [SPECT/PET Radioisotopes (Technetium, F-18)] & by Geography – Forecasting - 2017
[No of pages - 346 ] Browse 142 market tables and 44 figures/charts on Nuclear Medicine / Radiopharmaceuticals Market report segmented the global market by Applications (Cancer/Oncology, Cardiac), By Stable Isotopes (Deuterium, C-13),[SPECT/PET Radioisotopes (Technetium, F-18)] & by Geography – Forecasting - 2017
The Asia-Pacific nuclear medicine market size was valued at $4,116.43 million in 2020, and is projected to reach $8,957.89 million by 2028, registering a CAGR of 10.4% from 2021 to 2028.
Get World Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics - Market Opportunity and Forecast, 2014 - 2020 market research report Published by Allied Market Research. The Report is available at $4515 for Single User, and $10680 for Corporate User
Automated Radiosynthesis modules drive the production of radiotracer for PET and SPECT (Single-Photon Emission Computed Tomography) imaging in decentralized settings. These modules are user friendly, simple to set up, and offer scope of customized formulations of radiotracer for diagnostic and therapy administration, and hence their adoption will be increasing in near future. Automated Radiosynthesis Modules Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $32 million by 2022, registering a CAGR of 6.6% during the period 2016 - 2022.North America accounted for the largest share in terms of both market revenues and unit volumes, whereas Asia-Pacific region is expected to witness fastest growth rate during the forecast period. Read Full Report here: https://www.alliedmarketresearch.com/automated-radio-synthesis-modules-market Download Sample report @ https://www.alliedmarketresearch.com/request-free-sample/1761
Looking forward, the positron emission tomography (PET) market value is projected to reach a strong growth during the forecast period (2022-2027). More info:- https://www.imarcgroup.com/positron-emission-tomography-market
According to #TechSci Research report, Global Nuclear Imaging Equipment Market stood at USD4054.46 million in 2020 and is expected to grow at a CAGR of 6.51% by 2026. Gain More Insight: https://bit.ly/3v29zB4 Get Sample Report: https://bit.ly/3KdYyVJ Press Release: https://bit.ly/3LGMv3y Website: https://www.techsciresearch.com/ Market Research News: https://techsciblog.com/
According to the latest research by PMR, the global PET/CT systems market is expected to account for more than 3.0 billion US$ in terms of value, by the end of 2028. The PET/CT systems report also projects a significant growth potential, with an average Y-O-Y growth rate pegged at 6.2% through 2028.
The Radiopharmaceutical/Nuclear Medicine Market Report offers a complete picture of industry trends and factors along with quantitative data based on historical data and from various sources. Apart from this, the report also provides the market outlook, growth, share, size, opportunity and forecast during 2019-2025. Further, the report focuses on competitive landscape including company profiles of leading key players along with industry demand, future capacities, key mergers & acquisitions, financial overview in the global market of radiopharmaceutical/nuclear medicine.
The Global Contrast Media Market size is expected to reach $6.3 billion by 2025, rising at a market growth of 3.52% CAGR during the forecast period. Free Valuable Insights: https://www.kbvresearch.com/contrast-media-market/
Big Market Research “Global Contrast MediaContrast Agents Market” Size, Share, Industry Trends, Demand, Insights, Analysis, Research, Report, Opportunities, Company Profiles, Forecast to 2019. Visit for more info @ http://www.bigmarketresearch.com/global-contrast-mediacontrast-agents-2015-2019-market Contrast mediacontrast agents are chemicals used in diagnostic imaging procedures such as CT scans, MRIs, X-rays, ultrasounds, and related procedures. They enhance the internal structure of the body and provide high-quality images, which help in providing an accurate diagnosis. It is widely used in radiology, interventional radiology, and interventional cardiology.
Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications.
The report on United States Parkinson's Disease Drug Industry 2015 Market Research Report added by DecisionDatabases.com gives an in depth industry analysis of the market. It covers the costing, sales, revenue details and forecasts.
Title proposal for a regulation of the European Parliament and of the Council laying down Community procedures for the establishment of residue limits of ...
An introduction to MedicinesComplete * * * Remember me function allows users to log in once and remain logged in. Market focused product information allows ...
Global clinical trials imaging market @ http://tinyurl.com/jld56aj . Growth in pharmaceutical & biotechnology industries increase in R&D funding and increasing number of CROs are the primary growth drivers for this market during the forecast period (2015–2020). It is expected to reach USD 981.53 Million by 2020 from USD 724.87 Million in 2015, growing at a CAGR of 6.25%. The global clinical trials imaging market is segmented on the basis of products, modality and end-users. On the basis of products, the market is segmented into services & software.
This market is expected to reach USD 2.13 Billion by 2020 from USD 1.78 Billion in 2015, and is poised to grow at a CAGR of 3.6% during the forecast period.
North America (6), China (2), Japan (2), Europe (3), South Korea (1) and ... Vector Virology and Biotechnology Centre. Phase 2. Dubna Russia's 3rd Naukograd ...
Strategic foundation roles: Industry structure Strategic foundation Industry structure Customer value Business capabilities Competitive position To capture basic ...
Organizing and Managing a Radiopharmaceutical Production Unit A strategic alliance ... Infrastructure Implementation of Good Manufacturing Practice ...
Bob Tribe Former Chairman of PIC/S Benefits of PIC/S Membership for the Philippines * * * * * * * * * * * * * * * * * * * World Health Organization ...
Territory is 316,9 thou.square km (1,4% of the Russian territory) ... micro- and nanolevel engineering of bone tissue in orthopaedy and traumatology ...
... care more effective and less costly, especially by promoting the adoption of HIT ... FDG-PET scanning. For dementia and neurodegenerative disorders ...
MA Application Dossier? ?? ??? ???. 2. MA ???? Format Change. From 1st July 2003, ... to generate and compile different registration dossiers for all three regions. ...
The nuclear medicine market is projected to reach USD 5.26 billion by 2023 from USD 3.95 billion in 2018. Factors such as the growing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99, are driving market growth.